Thank you everyone for joining us today for Critical Care Grand Rounds. I'm super excited today to introduce to you our speaker, Dr. Jaisal Patel. Jaisal has been studying about B12 and the utilization of B12 in basoplegia and more recently in septic shock. I've been talking to him for, I don't know, it seems like a year now. We've been trying to organize this talk just because I think this story about the use of B12 in septic shock is so interesting and so compelling. But Jaisal is an associate professor of medicine at Medical College of Wisconsin. He did his fellowship training at the Medical College of Wisconsin. And interestingly, he complemented his training with a Nestle Clinical Nutrition Fellowship, sort of marrying his clinical trial and his research and his pulmonary critical care expertise with his knowledge in nutrition.
Jaisal, I am so happy to finally have you here and get to hear the story of B12 and septic shock. Thank you so much for joining us on this Friday afternoon. Thank you, Dr. Levine, for the invitation and for the warm introduction. It's always a pleasure to speak with you. And I'm thrilled to be here and to share this information. Let me just start by saying I have no disclosures. But more importantly, what I'll say is oftentimes when we think of objectives, we use words like discuss or identify or outline. I don't want to do that. And the reason I don't want to do that is because I want to just ask pointed questions. And I think that is just going to keep me accountable to all of you.
So if you ever feel like, hey, you didn't really answer this question, please just chime in and say, you know, can we talk about this a little bit more? But these are the questions that I'm hoping to answer or this talk will answer. I won't read them here, and I'll just kind of go through them as we move forward in the discussion. So the first component is, what is the current pathophysiologic understanding of septic shock? And I'm going to do this in a very abbreviated manner because I realize I'm preaching to the choir when it comes to this specific question right here. And so let's just talk about the evolution of vasodilatory shock.
I put these two up here, septic shock and postoperative, these other forms of vasobulatory shock, but I put these two up here specifically because I think this is where the crux of B12 utilization is occurring in today's healthcare settings. And as you all know, the inciting event for septic shock is often a pathogen, and more specifically, pathogen-associated molecular patterns. For postoperative, there's multiple events and mechanisms, really, but it could be blood that's returned to the patient that's full of, for example, activated proteins that lead to endothelial injury. It could be surgical trauma, ischemic repercussion injury, or endotoxin release from, say, gut hypoperfusion. Regardless, there's some form of endothelial injury or barrier dysfunction that occurs in these individuals. And the consequences are a cellular and circulatory dysfunction that often manifests as hypotension. And if it's not controlled, basal plesia.
And so what I call the circulatory gasotransmitters are nitric oxide and hydrogen sulfide. And you'll notice that what they have in common is that they're both elevated in septic and post-operative shock. And so I want to take just a little bit of a deeper dive into each of these gasotransmitters and sort of how they, you know, embroil the circulation. And so if we take a little bit of a deeper look, what we see here is that these inflammatory cytokines, specifically TNF-alpha, lipopolysaccharides from gram-negative, cell walls, autocoid, histamine, for example, they activate INOS and converts L-arginine into nitric oxide. And that nitric oxide will then ultimately diffuse from the endothelium to the adjacent vascular smooth muscle cell and cause vasodilatation. And it does that through the GCA and CGMP pathways. Now, it turns out that hydrogen sulfide is perhaps one of the underappreciated gazotransmitters in this story. And CSE stands for cystithionine gamma lyase. This is an enzyme that's upregulated. And what it does is it converts L-cysteine into hydrogen sulfide. Now, one of the problems with hydrogen sulfide is that there's not only endogenous...
production of sulfide, but there's certain bacteria that can generate hydrogen sulfide as well. Examples include Neisseria, E. coli, Pseudomonas Klebsiella. You know, gut amino acid metabolism can lead to hydrogen sulfide generation from some of these bacteria. And the problem is, is that nitric oxide will feedback and positively increase Cystothionine gamma liase, but the hydrogen sulfide will also increase INOS activity. So each one will cause the increased levels of the other. And particularly for hydrogen sulfide, it acts as a different mechanism.
to dilate vascular smooth muscle. And it does so by opening adenosine triphosphate-sensitive potassium germs. And that leads, as you all know, to increasing intracellular cyclic AMP, activates protein kinase A, and then that relaxes the smooth muscle and leads to the clinical phenotype of basal dilatory warm shock hypotension, if you will. So the question is, well, what's the impact of hydrogen sulfide in patients with septic shock? Now, I want to show you this U-shaped curve just to begin with, because this is to say that there's some...
degree of cytoprotection with hydrogen sulfide. In fact, very low levels of sulfide were found to be protective in patients with stage four heart failure. And those authors cited at the bottom left said it was under three micromoles per liter. Now, low levels were also found to be cytoprotective in the CNS as well, because what they've shown to do is they increase glutathione levels and protect cells from oxidative stress. Now, high levels on the right side of this curve were found to be deleterious in patients with basal dilatory shock. And the next four slides, I want to sort of unfold a story of how that has been observed.
Here's slide number one. And what this slide simply says is that sulfide levels are elevated early in septic shock. This was preclinical data from male rats, and they're randomly assigned into four groups. There's an endotoxin group. There was a control one group where it was endotoxin replaced with saline. There was a septic shock group where the rats underwent a sechal ligation to create septic shock. And then there's a second control group. And that second control group was nothing more than manipulation of the sepsis group, but their sechum was neither ligated nor punctured. And what you can see here.
particularly in the red and the light blue, which I hope it projects well on bars, is that the sulfide levels are elevated in all four of these different sites, the thoracic aorta, the pulmonary artery, the mesenteric artery, and the tail artery. So point number one is that hydrogen sulfide levels are elevated early in sepsis, particularly in this endotoxic shock group where it was the highest level. So then the next question is, so what's the molecular mechanism by which sulfide perhaps provokes the inflammatory response in sepsis? And so this study aimed to investigate signaling pathways that underlie the pro-inflammatory role of sulfide in signal ligation and puncture-induced sepsis. So the left-hand side of the screen is what you've already seen, but it's been replicated. And what you see in the black bar is that the plasma sulfide concentrations are elevated in the top graph. And the bottom graph, you'll see that the cystothionine gamma-lyase levels are elevated in the CLP model. On the right-hand side of the screen, what you'll see now is that the extracellular signal...
regulated kinase. Boy, that's a mouthful. ERK. ERK1 and 2 is a regulator of a nuclear effective beta activity, which is a fancy way of saying it's an extracellular signaling process that leads to the downstream production of more cytokines. What you can see here is that ERK1 and 2 are both elevated in the liver and in the lung in the septic model as compared to the sham models. So now what we've established is that from preclinical data is that sulfide levels are elevated. Those elevated levels can activate one of the signaling pathways in sepsis. And let's see what happens after that. And so this is the third slide.
And what this slide shows, there's two takeaways from this slide. The first takeaway is, if you look at this graph on the left, there's a rise in TNF-alpha level in both groups that underwent sepsis. Those are the second and fourth bars, okay? Importantly, where the cystothionine lyase was inhibited, that's the CLP plus PAG, that's the green that I've highlighted here. You can see that when that's blocked, the tissue TNF-alpha levels go down.
The second thing to note from this is that, and on the right, is the nuclear factor beta activity over time increased. And you can see that in the red bars here. And so this slide is to say that sulfide levels are elevated. Those sulfide levels being elevated activate the ERK signaling pathway. It's one of the signaling pathways in septic shock.
And that signaling pathway will then activate nuclear factor kappa beta, which then can lead to increases in some of these cytokines, notably in this study, TNF-alpha. Now, what I'm not showing you here is that there's also an increase in interleukin-1 beta, which is, again, another cytokine that's been implicated in the sustainment of septic shock. So slide number four is human data. And unfortunately, there's not much human data, but the human data that we do have is from non-surgical adult patients. So this study looked at 41 patients with septic shock. The plasma sulfide level in these patients was about 23 micromoles, and the lactic acid was about seven. So there's two takeaways from this study. On the left, there's a linear correlation between the norepinephrine dose at admission and total plasma sulfide concentrations. So in other words, sicker patients were correlated to have higher sulfide levels. And on the right,
the receiver operating curve for total plasma sulfide in the cell line compared to lactate in the dash line. And what you can see here is the authors concluded that for every one micromole increase in sulfide, there's about a 6% increase probability for mortality. But again, observational data, take it with a grain of salt. So the next question is, well, what preclinical data informed the role of intravenous hydroxycobalamine or vitamin B12 in septic shock, particularly now that we have a little bit more information on some of the gas transmitters that are important? So to give you some background information, when you're replacing B12, in your patients who might just have a B12 deficiency, you know, those who have gastric bypass, those who are metformin on PPI, pernicious anemia. This is the dose that you're giving them. You're giving them 0.001 grams and you're giving them to them over time monthly.
And this is, again, just for pure vitamin B12 deficiency. So what we're talking about here is super therapeutic level. We're talking about five grams. And we're talking about giving that over 15 to 30 minutes. This was cyanocit, which is known as, was licensed in 1996. And this was as an antidote. And it was used for impaired pre-hospital and in-hospital treatment of cyanide poisoning. Now, it turns out off-label use cyanocit or hydroxycobalamin is hydrogen sulfide toxicity. And this can occur in, you know, well drilling, gas refining industry accidents and such. But these are the two current sort of label and off-label uses of hydroxycobalamin.
Now, as an antidote for cyanide toxicity, this was a phase one safety study that was conducted in healthy humans. There are no randomized control trials, by the way, that have tested hydroxycobalamin in cyanide toxicity, right? But what this study did was look at 136 healthy humans that were given two and a half, five, seven and a half, or 10 grams of B12 or equivalent volume placebo. And what you can see here as denoted by the green arrows is that hypertension was a side effect. And you can see that this side effect of hypertension persisted for up to 24 hours compared to placebo, which is the bottom line.
on these two graphs. Now I'm showing you the five and 10 gram versus placebo doses. Let me take you back, and I want to take you back to like 1965, because it turns out that this is not such a new therapy after all. Now, this was out of Leningrad. It's now called St. Petersburg in Russia. But what I want to underscore here is this, which is vitamin B12 administered in sufficiently large doses contributes to a protracted stabilization of the presser effect from injection of the blood substitute and to survival of animals. And if you read the preceding sentences, this is compared to just IV injections of blood saline.
So this goes back a long ways. And it turns out that Greenberg, 30 years later, decided to revive the B12 story. So this was preclinical data. And he revisited the role of IVB12 in an LPS model of septic shock in rats. And what he found in the figure on the left, if you look, LPS was given at time zero. And the closed circles represent a change in map with B12. And the open circles represents saline. And the triangles represent pre-LPS infusion of hydroxycobalaminin.
And what you can see here is that in the closed circles and the closed triangles, the mean arterial pressure was greater compared to just saline in this LPS model of septic shock. And if we look at the figure on the right, note that more rats that were given hydroxycobalamine survived compared to those given LPS alone. And so the authors here concluded that hydroxycobalamine, as compared to LPS alone, saved these rats' lives. These authors took it a step further, and they tried to investigate some of the mechanisms of hydroxycobalamine. And so there's two takeaways from this particular slide. The first takeaway is that...
the plasma reactive nitrogen intermediates, that's RNI on the left side of the screen, go down after 48 hours. And that's highlighted in the red bar that I just put up on the screen. And then on the right-hand side, the urinary nitrogen concentrations go up. So it turns out that hydroxycobalamin is excreted in the urine. So the plasma nitrogen levels went down and the urinary ones went up. These authors concluded that hydroxycobalamin may limit the spillover of nitric oxide into the plasma. If we further the story, this is mice who were separated.
into the following groups, LPS only, and then two doses of hydroxycobalamin, 40 and 80 milligrams per kilogram. And there were 12 mice per group for three groups. And there's two takeaways from this slide. The first one is that there was a greater survival in mice that received hydroxycobalamin. All mice in the LPS group died within 24 hours. And you can see that in these figures. And then the second takeaway is that if you look at lung and liver expression of interleukin-1b, it was lower in mice that received hydroxycobalamin. And you can see that in these green bars right here. So in other words, the hydroxycobalamin not only can reduce the spillover,
of nitric oxide intermediates. But by doing so, you may limit the inflammatory response as well. So what about hydrogen sulfide? This is the one study that has looked at hydrogen sulfide toxicity. And this is a sheep study. And so here's what happened. Hydrogen sulfide gas was administered to sheep, and both saline and B12 were given. So 16 sheep were given 200 mLs of saline or 5 grams of IVB12. All right, so two things to note from this slide.
The figure on the left, the sulfide gas levels went up. This is the saline group. And femoral blood flow was reduced. And systolic blood pressure remained low. And if you look at the fractional excretion of sulfide, that's the middle bar there, you notice that that stayed elevated in just the saline alone. So in other words, when inducing hydrogen sulfide toxicity, saline didn't really have an effect on the hemodynamics.
But when they infused hydrogen sulfide gas and then gave adrexacobalamine to these sheep, what you can see here is that, yes, the gas levels went up, but look what happened. The femoral blood flow also was reduced, but then when the B12 was given, it went up, and the arterial blood pressure was restored as well, and hydrogen sulfide levels actually started to come down. So these authors seem to conclude that lowering of the sulfide levels through scavenging may augment the hemodynamic parameters that are observed in this study. And this, to me at least, is one of the most compelling randomized controlled trials in animals. And this was the first animal RCT testing B12.
And what they did, these authors did, was they took swine and they randomized them to 200 mg per bolus and then bolus of B12, norepinephrine to maintain the MAP, or just saline. And the reason I highlighted the weight for you is simply to say that when I did the calculations, it equated to about 9 to 10 grams of B12 using the weight that is shown on the screen there, about 47 to 48 kilograms in these swine models. And here's what was found. Notice the increase in MAP with hydroxycobolamine and with norepinephrine. That's the dashed line and the dotted line.
You'll see that in this model, when treatment was initiated, both of them was elevated. But if you look at the just saline alone, that's the solid line at the bottom, you can see that the mean arterial pressure didn't really fudge at all after hypotension was ensued with lipopolysaccharide. And this figure on the right, note 100% survival in the hydroxycobalamin group. Now, again, they give a pretty good dose of hydroxycobalamin, and they also followed it up with an infusion. But notice the survival was 100% in the animals that received hydroxycobalamin, and that was even compared to norepinephrine.
One of the other compelling components of this trial, again, in my opinion, is this right here. They measured multiple cytokines. I'm showing you some of the common ones that we see in septic shock. And as compared to control, look at the decrements in the TNF-alpha, the interleukin-6, and the interleukin-1 beta. Not so much TNF-1 beta, but compared to the norepinephrine group, the interleukin-1 beta. Again, these weren't statistically significant, but that doesn't mean they're not clinically significant, especially if we see a survival of benefits. And I wonder if it was just a power issue that didn't make them statistically significant. But again, we're seeing also...
perhaps some mechanistic components here where we see some downstream reductions in inflammatory markers. So I've given you a lot of information. So let me just pause here and give you a summary of the role of the gazotransmitters and the mechanism of hydroxychloroquine in septic shock. So number one, plasma, sulfide, and nitric oxide are elevated early in septic shock and contribute to basal dilatation. Number two, plasma, hydrogen sulfide activates the pro-inflammatory pathway. And the preclinical data I showed you was how it activates ERK1 and 2, which then activates nuclear factor, kappa beta, and then elevated TNF alpha and interleukin 1.
beta. Number three, it's a single observational study, but I take it for what it is, but higher norepinephrine dose was associated with higher plasma sulfide concentrations, which is associated with an increased risk for mortality. And then number four, the mechanism by which hydroxycobalamin may work is that it scavenges nitric oxide and sulfide, limits its spillover, in other words, serves as a sink, and reduces the inflammatory response in septic shock. So let's move on to human data. So what data in humans informs the role of IV hydroxycobalamin?
in basal dilatory shock. And I use this word basal dilatory intentionally, not septic, because I want to show you that we just have a positive data in that space. And so this was work that we summarized a few years ago. And what I'm showing you here are liver transplantations and then post bypass. And the first report was by Roderick about 10 years ago, where again, these are all single case reports. There've been many since, but this was a 71 year old man who had a cabbage. And what you can see is that the norepinephrine dose was, you know, halved after hydroxycobalamin. Now there's three points that I want you to take away from this slide. The first one is that you'll see that almost
All of these case reports, and even the subsequent ones since, have used about five grams of hydroxycobalamin. There were two of them that used a continuous fusion. The duration in some ways varied, but overall it was 10 to 15 minutes in most of the case reports. And then number three, you can see here that the post-hydroxycobalamin norepinephrine dose was lower in all of these case reports. Now, what about septic shock? So this was a recent systematic review. And this systematic review looked at hydroxycobalamin compared to methylene blue in vasodilatory hypotension. And they looked at all studies that reported vasodilatory shock. And of the 26 or so studies, only two reported patients with septic shock. This is the first one. The first one is by Ritter et al. This was a large series. Now, notice, if you look at the clinical details or conditions column, 71% had septic shock. So they weren't all septic shock, but 71% were septic shock.
The other thing to look at is these patients were sick. The norepinephrine dose prior to these infusions was fairly high, 0.65 mics per kg per minute. And post-infusion, it wasn't very different. And these patients had almost an 80% inpatient mortality. Now, one of the key criticisms of looking at this particular study was that A, it was observational. B, there was a control group. And then C, about three quarters of patients had received methylene blue prior to receiving hydroxycobalamin. So it wasn't an apples to apples comparison. Now, if we look at the second study, and this is by Sacco and colleagues, this was 26 patients.
with septic shock. And these were all patients with septic shock, by the way. Again, if you look at their norepinephrine doses, they were again, fairly high, not as high as the Ritter, but the inpatient mortality was still exceeded 70% as well. And if I give you just a little bit of a deeper dive into the SACO study, this was again, a single center report, 26 patients over 17 months. The median age was about 70 and the mean map prior to was about 62. And what I want to show you here is that the map increased by 16 millimeters of mercury at one hour.
14 at six hours and another 16 at 24 hours. This was relative to the baseline map. And this was with just hydroxycholabalamin. One patient out of 26 or 4% received methylene blue. And so that's why I think it's probably a little bit more of a fairer comparison. But again, single center report, retrospective, no control group are some of the limitations. And again, these patients were fairly advanced in their disease trajectory.
Based on the lack of prospective data, however, we have biologically plausible data that suggests that hydroxycobalamin can reduce vasopressor support in preclinical models of septic shock. We were compelled and motivated to conduct a pilot feasibility study. This was initiated prior to COVID. And so initially, our sample size called for 13 patients per arm. And we had power to study.
based on the ATHOS-3 trial, which was a 15% improvement in the mean arterial pressure at three hours. Unfortunately, you know, we had to switch to a feasibility study because we weren't sure if we could even execute it in the context of COVID. And so we chose a convenient sample of 20 patients and we executed a feasibility study and we still achieved enough power for our primary outcome of feasibility. But here's what we did. 10 patients randomized to a single five gram dose of hydroxychloroquine over 15 minutes or a placebo, which was 200 mLs of saline over.
15 minutes. You can see our primary outcomes of feasibility. And these included the feasibility of achieving protocol and laboratory compliance, the latter of which I'll explain in just a little bit. And then we wanted to look at some secondary clinical outcomes that may help us power future trials. But we also wanted to try and establish some mechanisms that hadn't been looked at previously, which is pre and post infusions of plasma sulfide levels. Because if truly hydroxycholamine was going to work, well, then it should work by reducing plasma sulfide.
Here were our inclusion and exclusion criteria. Full disclosure, if you look at inclusion criteria number four, our initial criteria was 0.2 mics per kg per minute. But again, we were aiming for an early target for these patients with septic shock because we think that's where they would derive the most benefits. So we changed it to 0.1 mics per kg per minute. And then if you look at our exclusion criteria, row number two, the axochondric indications, the biggest ones were anaphylaxis to hydroxycopylamine. And then number two was a history of calcium oxalate nephropathy because one of the side effects of hydroxycopylamine is calcium oxaluria.
And so here are our baseline characteristics. And what I'll draw your attention to are, number one, the norepinephrine dose at T0. And this was at the time of randomization. This was, again, fairly sick patients, 0.3-ish in both groups. And number two, severity of illness, again, sick patients as defined by the SOFA and the Apache 2 scores. And then number three, you'll notice that these were vast majority medical ICU patients. And we actually have a trial running, we'll be running soon, actually, in surgical cohort with sepsis, because we think that they represent a different population.
And so here are the outcomes of that pilot trial. We achieved 100% clinical laboratory protocol compliance, and we had a zero of contamination rates, meaning all patients were randomized to placebo, got just placebo, none of them got, you know, hydroxycobolamine. And then we established a pre-COVID enrollment rate of 1.25 patients per month and overall 1.05. And then here are our secondary outcomes. Let me orient you to what T0, 1, 2, and 3 mean. T0 is that randomization.
T1 is one minute before we started the infusion of hydroxycobalamin. T2 is at 30 minutes and T3 is at three hours. And what you can see here is that there was a, what I think is a clinically meaningful and statistically significant change in vasopressor dose. This was norepinephrine equivalent dose between T1 and T2, as well as T1 to T3 in the hydroxycobalamin group as compared to placebo. And then we also got a greater absolute difference in the plasma-free sulfide levels in the intervention arm. Now, again, 10 patients per arm, not sure what to make of it. But notice, we're not sure if this represents a meaningful, clinically important difference yet. But what we've at least established is that we can measure free sulfide levels. And number two, the levels were lower, or they actually changed more so in the drug arm compared to placebo.
And so finally, I want to talk just a little bit about the safety profile of hydroxycobalamin and maybe just address some common things that come up about its use. So this is data from where hydroxycobalamin has been used as an antidote for cyanide toxicity. This was approved in France. And so this has been around in France for a little while. And so the data I'm going to show you for cyanide toxicity comes from France. And so what this graph shows is 12 patients that were hemodynamically unstable. And so this was a retrospective study, about eight years, 101 patients with cyanide poisoning. And the reason I'm showing this to you is because...
Number one, the patients who had cyanide intoxication who received hydroxychloroquine, of the 12 who were hemodynamically unstable, the blood pressure was recovered in nine of them. But the second thing I want to show you is that the blood pressure in 11 out of 12 of those patients never got above 150 millimeters of mercury, the systolic blood pressure. And in the one patient where it did get above 180 millimeters of mercury, when we start thinking about hypertensive crises, there were no adverse events reported. So again, even though the blood pressure went up, there were zero hoc-related elevation blood pressure adverse events reported. This is a prospective study. And this prospective study was from 87 to 94. And it was smoke inhalation, about 70 patients, 42 of them who had cyanide toxicity. And what I'm drawing your eyes to here is the red triangle. And again, what you can see here is the pre-infusion and then the end of the first infusion of blood pressure. And then the median systolic blood pressure on arrival to the ICU. And again, what you can see is that they reported hypertension in three of these patients, but there were zero adverse events that were reported.
Now, let me take you back to this randomized control trial on healthy humans. This was, again, 136 healthy humans who were given two and a half, five, seven and a half, 10 grams of B12 versus placebo to see what some of the side effects were. Again, the side effect was hypertension, but did that hypertension cause any adverse outcomes? And so busy slide, let me draw your attention to these rectangles and the smaller rectangles within the large rectangle. And what this shows is that this is the maximum change in the systolic blood pressure.
at hydroxychloroquine at doses of 2.5, 5, 7.5, and 10. And what you can see here is that in this, it never got above 180, and there were no adverse events related to hypertension that were reported. So what adverse events were reported? So in this largest trial, and I'm sure many of you, especially if you've used hydroxychloroquine, know this, chromateria, 100% of patients developed chromateria. And this is actually one of the reasons why it's so difficult to blind such a trial. Now, in our pilot trial, we did mask all the tubing, mask the actual infusion bag. But despite that,
When the urine turns this Merlot color, it's very easy to recognize who received hydroxycobalamin. So this is a cosmetic effect. This is just the color of the drug. It doesn't mean anything in terms of injury to the GU system. It's more so just a cosmetic effect. And then the second most common was erythema. And this was a self-limited erythema. It was reported over 90% of patients in the five gram group and 100% of patients in the 10 gram group in that healthy human RCT. Again, self-limited, usually within 48 to 72 hours, it goes away. It causes, I think, more distress to the patient to seeing it as opposed to it actually causing physiologic harm. And then this oxalate crystals in the urine.
Notice it's about half, it's a little more than half in this RCT. And what we don't know is whether this just represents an epiphenomena, meaning it's just there, versus it actually causes nephropathy. Now, in the Health and Human Study, it didn't cause any nephropathy. There wasn't nephropathy reported. But imagine seeing this in a patient who has acute kidney injury and septic shock. How do you differentiate whether it's just there versus it's actually causing a nephropathy? Now, in our trial, we didn't have any serious adverse events. And adverse events were unexplained death. And the way we talked about through that was if you're giving somebody hydroxycobolamine and they succumb.
during the infusion. That would be considered an unexpected death. And then new acute injury related to calcium oxalate nephropathy after randomization. The other thing that comes up is laboratory interference. And this comes up in a handful of cases, especially when you need to frequently measure hemoglobin or bilirubin. These are calorimetric assays where there can be some interference and false positive and false negatives, but we didn't have any reported laboratory interference. And then finally, this is a question that I've gotten asked, which is what is the impact of hydroxychloroquine dialysis?
And so some of your dialysis machines may have gone off when you gave hydroxycobalamine. And so this was a study from 2017, and there have been reports since. But the reason I chose this study is because it sort of summarized what some of the previous studies had in common. And so I'll draw your attention to this rectangle right here. And this is the dialysis machine that's been implicated as causing the alarms to go off. Again, I don't want to use trade names, but it's called the Fresenius 2008K dialysis machine. And so this is what that machine looks like.
Now, this machine contains a blood leak alarm, and it contains a blood leak alarm that consists of two color light sources that monitors the clarity of the effluent. And so that photo detector is triggered when the green light is absorbed by blood. Well, this machine thinks sidrexicobalamin is blood because it absorbs a green light when the alarms go off, thinking that there's a blood leak. We actually use the Fresenius next stage machine, which is in the middle. And then I've got colleagues around the country who use the Baxter Prisma Flex. And it turns out that these machines have a single optical emitter to detect light scatter. It doesn't actually absorb light, but it just takes a scatter of light. And so the latter method, again, does not depend on light absorption, and it cannot therefore incriminate tigrexacobalamine as representing blood. And this is why in some of our patients who are on continuous renal replacement therapy, we did not have machines go off because of the use of this Fresenius next stage machine.
So I gave you a lot of information. So let me just summarize. Nitric oxide and hydrogen sulfide levels are elevated early in sepsis and septic shock. And preclinical data suggests sulfide can enhance the inflammatory response. Remember, through the ERK and then the nuclear factor kappa beta pathways. And then higher sulfide levels are associated with a greater severity of illness and worse outcomes in septic shock. But preclinical data seems to suggest that hydroxycobolamine improves hemodynamics and survival in septic shock. And it does so by scavenging nitric oxide, eliminating it in the urine.
and then scavenging hydrogen sulfide, and then leading to some downstream reductions in the inflammatory response. And then delivering hydroxycopalamine in patients with septic shock is feasible, and compared to placebo, is associated with reduced vasopressor dose and lower post-infusion-free sulfide levels. And this was, again, demonstrated in the pilot trial. And then finally, the plethora of evidence seems to suggest that hydroxycopalamine is safe, and the biggest side effects are chromaturia and then that self-limiting rash that we had talked about. And then the impact of dialysis appears to be related to the type of machine and the circuit, but particularly those machines that rely on the absorption.
of green lights by hemoglobin as a trigger for the alarm to go off. And so we are currently in the stages of developing a phase three multicenter of efficacy trial. It'd be called the HOX-2 trial. And we are planning to enroll 850 patients and randomize them to a single five gram dose of hydroxycobalamin over 30 minutes or equivalent volume saline over 30 minutes. And we're looking at the primary outcome of change in ventilator and vasopressor free days by day 28, which is a...
composite outcome. We'll have some additional secondary mechanistic outcomes and looking also at outcomes related to the heterogeneity that may inform heterogeneity of treatment effect. And please email me if you're interested or wanting to join the collaboration. Thank you so much for your attention and the invitation to speak with you today. I'm happy to take questions.